All In Biotech

Drug Trial Radar · NCT07549490

Human Experimental Models of Pain (HEMP)

A Pilot Study for Developing a Comprehensive Signal Detection Approach for the Mechanisms of Action and Analgesic Efficacy of Two Analgesics Using Human Experimental Models of Pain (HEMP)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Nov 25, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Sponsor type
NIH
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain. The study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen). Up to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit. The study includes several experimental pain tests. These include: a heat and capsaicin skin test that causes short-term skin sensitivity, a UVB light test that causes a temporary sunburn-like sensitivity, and a cold pressor test, in which a hand is placed in very cold water for a short time. Participants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done. Each treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks. This study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....

Conditions

  • Acute Pain

Interventions

  • PlaceboDrug

    Over-encapsulated matching placebo administered as a single oral dose in one treatment period of this randomized, double-blind, 3-period crossover study. The placebo is made to look identical to active study drug capsules to maintain blinding. Each participant receives placebo once, with at least 48 hours washout between treatment periods.

  • NaproxenDrug

    Over-encapsulated oral naproxen, 550 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives naproxen once, with at least 48 hours washout between treatment periods.

  • PregabalinDrug

    Over-encapsulated oral pregabalin, 300 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives pregabalin once, with at least 48 hours washout between treatment periods.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in pain intensity after cold pressor testTime frame: Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
  2. Change from baseline in pain intensity for allodynia (soft brush) after first heat/capsaicin pain model applicationTime frame: Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
  3. Change from baseline in pain intensity for hyperalgesia (pin-prick) after first heat/capsaicin pain model applicationTime frame: Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
  4. Change from baseline in pain intensity for mechanical hyperalgesia (pin-prick) at the UVB siteTime frame: Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
  5. Change from baseline in pain intensity for thermal hyperalgesia (heat pain) at the UVB siteTime frame: Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.